Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of adjuvant remifentanil, dexmedetomidine, or metoral with thiopental on hemodynamic status during electroconvulsive therapy in major depressive disorder
IRCT20141209020258N178Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of remifentanil, dexmedetomidine, metoprolol and thiopental in major depressive disorder (MDD) (3 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Hemodynamic status during electroconvulsive therapy. Started Jan 2023; status: completed.
02
Drugs
remifentanildexmedetomidinemetoprololthiopental
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20141209020258N178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N178.